• linkedin
  • Increase Font
  • Sharebar

    A promising target for immunotherapy?

     

    The immune co-stimulatory molecule B7-H4 is highly expressed in the luminal subtype of bladder urothelial carcinoma and is associated with poor survival. B7-H4 may be a promising target for immunotherapy, particularly in patients who do not respond to PD-L1 therapy.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results